DAWEX/CEA
28.5.2024 09:31:30 CEST | Business Wire | Press release
Dawex and CEA today announced that they have signed a partnership agreement to create a joint Research & Development Laboratory. Aiming at conceiving and developing technological solutions to catalyze truly impactful innovations in the field of data ecosystem, the collaboration between the CEA and Dawex will feed responses to global industry challenges to shape a more sustainable & resilient future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528953935/en/
The creation of secure, trusted and interoperable data ecosystems and data spaces has become crucial in fostering trusted artificial intelligence and realizing a sustainable and digital society. Data exchange and data circulation are at the forefront in boosting transformative solutions such as Generative AI, while pushing the boundaries of innovation thanks to Privacy Enhancing Technologies integration —ultimately making such disruptive technologies accessible to customers.
Since its inception, Dawex has been investing in Research & Development, in order to bring the perfect conditions for secure, trustworthy, sovereign and compliant data exchange. Dawex will bring to this collaboration its extensive and proven expertise in secure data exchange, data governance, interoperability, standards & norms. Through active engagements in developing the most advanced data exchange solutions and contributing to regulations, norms & de facto standards, Dawex has been demonstrating its leadership as a strategic market player, notably by powering the largest number of European data spaces.
The CEA participates in accelerating industry transformation with programs on the factory of the future, digital twins, artificial intelligence, and digital trust. It ultimately contributes to building a powerful innovation ecosystem guided by the values of social and environmental responsibility.
“Innovation and Research have been in Dawex DNA since Day-1. We are committed to advancing data exchange matters and address forward looking data challenges, delivering the most sophisticated data exchange technology” said Fabrice Tocco, co-CEO at Dawex. “We are extremely happy to collaborate with the CEA and co-innovate to bring the next-generation innovations that will transform data exchange,” concluded Mr Tocco.
”Data exchange plays a major role in the industry transformation that France and Europe are facing today. This leads CEA to partner with Dawex as a leading company in the field of data exchange and data ecosystems”, declared Alexandre Bounouh, CEO of CEA List institute. “Creating together a common R&D laboratory will enable us to bring thorough and trusted digital solutions to the industry with one objective in mind: to accelerate transitions and among them energy & climate ones. We are delighted to pursue this ambition with Dawex”.
About Dawex
Dawex is the leader in Data Exchange solutions to distribute or share data products, with trust, for any business case, in compliance with data regulations. With Dawex Data Exchange technology, organizations create data ecosystems and data spaces such as Corporate Data Hubs, Industry Data Hubs and Data Marketplaces to address economic, environmental and decarbonation challenges. At the invitation of the United Nations, Dawex joins the Data expert group of the United Nations Environment Program. Awarded Technology Pioneer by the World Economic Forum, Dawex is also the initiator of an international standardization program on Trusted Data Transaction. Created in 2015, Dawex is headquartered in France, expanding business operations to Europe, Asia, North America and the Middle East.
About CEA
The CEA is a major research organisation working in the best interests of the French State, its economy and citizens. Thanks to its strong roots in fundamental research, it is able to provide tangible solutions to meet their needs in four key fields: low-carbon energy, digital technologies, technologies for medicine of the future, defence and national security.
As the world's leading innovator among public research organisations (Clarivate 2024), the CEA acts as a catalyst and accelerator of innovation for French industry. It helps businesses in all sectors be more competitive, creating high-performance products that stand out from the crowd and developing trail-blazing solutions that lead to changes in society. The CEA deploys this dynamic in all regions of France aiding local partners to innovate themselves, thus helping to create sustainable value and jobs nationwide, tailored to meet actual industry needs. At the same time, it supports the development of its 250 start-ups, agile vectors for transferring the disruptive technology and knowledge developed at CEA laboratories to industry. More information: https://www.cea.fr/english
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528953935/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom